trial · primary record
obrixtamig
Small Cell Lung Cancer (SCLC)
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 670 |
| Primary completion | 2029-07-30 |
| Primary endpoint | Overall survival (OS) |
| Registry ID | NCT07472517 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:27.182Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07472517
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Obrixtamig · compound